Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma

We report a case of malignant pheochromocytoma recurred after debulking surgery. A 17-year-old male patient visited our hospital for right flank pain. He had not experienced palpitations, headache, sweating or weight loss. Level of urinary catecholamine and its metabolite increased above normal valu...

Full description

Saved in:
Bibliographic Details
Published in:Japanese Journal of Clinical Oncology 2009, Vol.39 (5), p.327-331
Main Authors: Park, Kyung-Sun, Lee, Jae-Lyun, Ahn, Hanjong, Koh, Jung-Min, Park, Inkeun, Choi, Jun-Seok, Kim, Yi Rang, Park, Tai Sun, Ahn, Jin-Hee, Lee, Dae Ho, Kim, Tae Won, Lee, Jung Shin
Format: Report
Language:English
Subjects:
combination chemotherapy
malignant pheochromocytoma
sunitinib
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of malignant pheochromocytoma recurred after debulking surgery. A 17-year-old male patient visited our hospital for right flank pain. He had not experienced palpitations, headache, sweating or weight loss. Level of urinary catecholamine and its metabolite increased above normal values and abdominal computed tomography showed a huge right adrenal mass. One month after debulking surgery, anterior mediastinal and multiple liver metastases were found. These tumors had no response to two conventional regimens of combination chemotherapy (cyclophosphamide, vincristine, dacarbazine and anthracycline; and etoposide and cisplatin). We treated the patient with sunitinib, a multiple tyrosine kinase inhibitor. The tumor showed very good metabolic response to the therapy. In patient with malignant pheochromocytoma, sunitinib might be one therapeutic strategy for malignant pheochromocytomas.
ISSN:0368-2811
1465-3621
DOI:10.1093/jjco/hyp005